Sulfamethoxypyridazine

Summary

Sulfamethoxypyridazine (CHEMBL268869) is an approved small-molecule antiinfective agent (ATC J01ED05); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01ED05
• Indications: 1 condition
• Chemistry: 280.31 Da · C11H12N4O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL268869
Name	Sulfamethoxypyridazine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5330
ChEBI	CHEBI:102516
ATC	J01ED05
Molecular formula	C11H12N4O3S
Molecular weight	280.31
InChIKey	VLYWMPOKSSWJAL-UHFFFAOYSA-N

SMILES: COC1=NN=C(C=C1)NS(=O)(=O)C2=CC=C(C=C2)N

IUPAC name: 4-amino-N-(6-methoxypyridazin-3-yl)benzenesulfonamide

ChEBI definition: A sulfonamide consisting of pyridazine having a methoxy substituent at the 6-position and a 4-aminobenzenesulfonamido group at the 3-position.

Pharmacological roles (ChEBI): antiinfective agent, EC 2.5.1.15 (dihydropteroate synthase) inhibitor, drug allergen.

Also known as: CL-13494, Depovernil, Lederkyn, NSC-757875, Retasulphine, Succinylsulfathi, Sulfamethoxypyridazine, Sulfamethoxypyridazinum, Sulfametoxipiridazina, Sulfasuxidine, SID11112213, SID7971832

Patent coverage: 1,485 distinct patent families (4,235 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 4,026 (95%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Survival motor neuron protein, Prelamin-A/C, Beta-lactamase, Cytochrome P450 2C19.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 5 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	8.46	Potency	3.5	nM	CHEMBL_ACT_3637756
SMN1	7.35	Potency	44.7	nM	CHEMBL_ACT_3878369
CYP2C19	5	Potency	10000	nM	CHEMBL_ACT_4017454

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).